Compare VNDA & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNDA | KIO |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | 2400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 441.5M | 474.6M |
| IPO Year | 2006 | N/A |
| Metric | VNDA | KIO |
|---|---|---|
| Price | $8.10 | $11.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.63 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 136.5K |
| Earning Date | 02-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,074,000.00 | N/A |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $24.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.12 | N/A |
| 52 Week Low | $3.81 | $10.52 |
| 52 Week High | $9.60 | $13.59 |
| Indicator | VNDA | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 49.99 |
| Support Level | $7.14 | $11.43 |
| Resistance Level | $7.82 | $11.73 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 62.09 | 64.06 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.